Biogen will soon launch an open-label trial to start re-dosing aducanumab — an injectable treatment under development —…
Articles by Ana Pena, PhD
Researchers have discovered a likely reason why the most common form of the CD33 protein…
[Editor’s note: This story, published on Dec. 10, was updated on Dec. 16 with additional details provided by Acadia Pharmaceuticals.]…
Biohaven announced that its Phase 2/3 study of the investigational oral therapy troriluzole (BHV-4157) in treating symptoms of…
The second part of a clinical study evaluating the use of a blood diagnostic test for Alzheimer’s disease —…
Biogen is planning to seek approval for aducanumab, an injectable treatment under investigation for patients with early…
Genentech, a subsidiary of Roche, has launched a new substudy…
Alzheimer’s oral therapy candidate PRI-002, being developed by…
Elenbecestat and BAN2401, two potential anti-amyloid therapies, were selected by the…
An online program that teaches how to focus on positive emotions can help caregivers of family members with…